Novo Nordisk A/S (NVO) Expected to Announce Quarterly Earnings on Wednesday

Novo Nordisk A/S (NYSE:NVO) is projected to issue its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of $0.87 per share and revenue of $11.1155 billion for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 7:00 AM ET.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, analysts expect Novo Nordisk A/S to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $43.84 on Monday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The company has a fifty day moving average of $38.50 and a two-hundred day moving average of $47.19. The stock has a market capitalization of $195.76 billion, a PE ratio of 12.64, a P/E/G ratio of 10.42 and a beta of 0.77. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were given a dividend of $1.2751 per share. The ex-dividend date was Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio is currently 50.43%.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA moves to restrict mass compounding of GLP‑1 active ingredients, which would make it harder for copycat/compounded alternatives to scale and should help protect branded pricing and volumes. FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Novo will start shipping its oral Ozempic (semaglutide) tablets in the U.S. on May 4, expanding its addressable market beyond injectables and helping defend diabetes sales as pricing pressure mounts. Ozempic pill available in US
• Positive Sentiment: Distribution/access wins (WeightWatchers Med+ and GoodRx adding the Ozempic pill) should support uptake and patient access for the oral launch. WeightWatchers expands access to Ozempic pill
• Neutral Sentiment: Analysts’ consensus still shows material upside vs. the current price (average target ~$65.56) and small EPS estimate tweaks from Erste Group — supportive context but not immediate drivers. Analyst price targets
• Negative Sentiment: Canada approved a second generic semaglutide (Apotex), signaling increasing global generic competition that could undercut Novo’s pricing and margins in core markets over time. Canada approves second generic version of Ozempic
• Negative Sentiment: Eli Lilly’s Q1 beat, raised guidance and approval/rollout of Foundayo (an easier-to-take oral GLP‑1) widen competitive pressure on Novo’s weight‑loss franchise and could lead to share loss. Lilly’s Double-Beat Widens the GLP-1 Gap
• Negative Sentiment: Ongoing concerns around pricing pressure and margin compression in the GLP‑1 market could make NVO’s recent rebound vulnerable if generics and convenience-focused rivals keep gaining traction. Pricing pressure and falling margins analysis

Institutional Investors Weigh In On Novo Nordisk A/S

A number of hedge funds have recently modified their holdings of NVO. Revolve Wealth Partners LLC raised its position in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after buying an additional 10,758 shares during the last quarter. Sivia Capital Partners LLC grew its holdings in shares of Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after purchasing an additional 1,587 shares during the period. Invesco Ltd. grew its holdings in shares of Novo Nordisk A/S by 26.3% in the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock valued at $28,967,000 after purchasing an additional 87,467 shares during the period. Finally, Gamco Investors INC. ET AL purchased a new stake in shares of Novo Nordisk A/S in the second quarter valued at about $314,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on NVO. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Wolfe Research began coverage on shares of Novo Nordisk A/S in a research report on Thursday, March 26th. They set a “peer perform” rating for the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Kepler Capital Markets cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, TD Cowen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective for the company. in a research report on Tuesday, March 10th. Four investment analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.